TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05458778

Intervention type: DEVICE
Intervention: Daily test with urine by the product
Description: Women perform the hCG test and share the test results
Study: NCT04735614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posthorax Thoraxbelt
Description: The patients will be assisted to put on the ThoraxBelt after the surgery by our research member and will be asked to keep it on except for during showering through the whole study period.
Study: NCT04802200

Intervention type: OTHER
Intervention: Data collect
Description: Data collect following a vascular closure by MANTA
Study: NCT04969289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dr. Eric Digital Health Intervention
Description: Dr. Eric is a user-informed, theory-based, digital health intervention that aims to improve adolescent male SRH. This ED-based intervention consists of two parts-an interactive, tailored app and 3 months of personalized, two-way text messaging. It is based on an evidence-based sexual health curriculum we developed using established behavioral theories, prior literature, input from key stakeholders, qualitative patient interviews, and our prior ED-based work.
Study: NCT04149418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Low-fat flavored yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt
Description: Low-fat flavored yogurt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control food
Description: Low-fat flavored soy pudding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control food
Description: Low-fat flavored soy pudding
Study: NCT04938791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric activity
Description: Participants will do elevation of upper limbs and mantain a 90º degree flexion position in an unsupported way.
Study: NCT05423418

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A244
Description: Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A244
Description: Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A244
Description: Dose of A244 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B.63521
Description: Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B.63521
Description: Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B.63521
Description: Dose of B.63521 is 300μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 50μg ALFQ
Description: Dose of ALFQ is 50μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 100μg ALFQ
Description: Dose of ALFQ is 100μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 200μg ALFQ
Description: Dose of ALFQ is 200μg. Vaccine will be administered via IM injection into the same deltoid muscle (same side) for all injections at Month 0 (Day 1), Month 1 (Day 29), and Month 2 (Day 57).
Study: NCT05447286

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
Study: NCT05241301

Intervention type: OTHER
Group type: OTHER
Intervention: one to one interviews
Description: one to one interviews to explore the perspective of family carers of older adults of Turkish and Moroccan origin in Flanders and Brussels, Belgium, concerning advance care planning (ACP)
Study: NCT06100952

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
Description: Drug: Ribostat riboflavin and sodium iodide ophthalmic solution~Device: UV-3000 ultraviolet A light source

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and sham treatment
Description: Drug: placebo ophthalmic solution~Device: UV-3000 light source
Study: NCT06051513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment with or without colistin
Description: For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with or without colistin
Description: For patients in this treatment group, colistin based therapy is used. Colistin combined with metroperan or imipenem（MIC≤8mg/L），or colistin combined with tigecycline, or colistin combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae. For patients in the control, best available treatment without colistin is uesed; Ceftazidime-avibactam, tigecycline combined with metroperan or imipenem（MIC≤8mg/L）, tigecycline combined with aminoglycosides (amikacin) are suggested to treat patients diagnosed with hospital-acquired pneumonia or bloodstream infection caused by carbapenem-resistant enterobacteriaceae.
Study: NCT05203653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise only
Description: Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise plus cool down
Description: Participants will perform 3 sets of 8 repetitions of 7 different exercises while in a fasted state followed by a 10-minute light aerobic cool down
Study: NCT05447286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 at 50 mg and 150 mg doses versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study over 6 experimental sessions.
Study: NCT05676658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coherent breathing
Description: Guided audio of coherent breathing pre-recorded by trained breathwork facilitator: \~5.5bcpm (with equal inhalation/exhalation durations of \~5.5secs each) for \~10mins/day over four weeks / 28 days. Delivered remotely through audio link.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo coherent breathing
Description: Same audio of coherent breathing but paced at: \~12bcpm (with equal inhalation/exhalation durations of 2.5secs each) for \~10mins/day over four weeks / 28 days.
Study: NCT05645198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oozfix
Description: Directly apply carboxymetyl starch (Oozfix) 5 gram evenly at the suprapancreatic surgical bed after gastrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Greenplast
Description: Directly apply Greenplast (Aprotinin 1000kIU/mL, Thrombin 500IU/mL, Fibrinogen 95mg/mL) 4 gram evenly at the suprapancreatic surgical bed after gastrectomy
Study: NCT05941806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pr Sandoz Tamsulosin
Description: Sandoz Tamsulosin, the study drug, is an alpha1-adrenergic blocking agent approved by Health Canada for men with bladder outlet obstruction symptoms associated with benign prostatic hyperplasia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose
Description: Patients assigned to the placebo group will receive glucose capsules according to the same protocol. The glucose capsules will be manufactured by the pharmacy of the CHU de Quebec
Study: NCT05643235

Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Description: Patients initiating BTK inhibitors will be offered the option of monitoring using the Medtronic Insertable Cardiac Monitor (ILR). The device will be implanted by a certified and credentialed electrophysiologist to enable monitoring to begin at least 24 hours prior to the first administration of the BTK inhibitor. Monitoring data will be collected prospectively until the patient withdraws consent, the device is removed, or up to 60 months
Study: NCT05681858

Intervention type: DIAGNOSTIC_TEST
Intervention: CT coronary angiography and [12N] NH3 PET-MR
Description: Advanced coronary artery plaque analysis, myocardial ischemia and coronary flow reserve
Study: NCT05623722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound-guided erector spinae plane block is performed at thoracic (T) level 8. An 18F catheter is placed on both sides of the thoracic vertebra deep into the erector spinae, and a bolus of 20 ml of 0.375% ropivacaine is administered bilaterally. Then, a continuous infusion of 20 ml of 0.375% ropivacaine on each side is followed at a rate of 2 ml/h every 12 hours. The intervention ends on day 7 or ceases when the patient is discharged from the ICU, died, or withdrew their consent.
Study: NCT05325580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: magnesium group 1g paracetamol + 20 min infusion of 2 g magnesium in 150 ml of saline serum and Placebo Group~1g paracetamol + 20 min infusion of 150 ml of saline serum
Study: NCT05885217

Intervention type: OTHER
Intervention: measure serum MicroRNA in acne vulgaris
Description: Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)

Intervention type: OTHER
Intervention: measure serum MicroRNA in acne vulgaris
Description: Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)

Intervention type: OTHER
Intervention: measure serum MicroRNA in acne vulgaris
Description: Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)

Intervention type: OTHER
Intervention: measure serum MicroRNA in acne vulgaris
Description: Quantitively assay of serum microRNA level will be measured control by performing an enzyme-linked immune sorbent assay (E LISA)
Study: NCT04751617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation will include: early mobilization with frequent posture changes and simple exercises in bed taking into account the patient's respiratory tract. Respiratory physiotherapy will also include improving diaphragm function along with training additional respiratory muscles. Active exercises of the upper limbs will be accompanied by gradual muscle strengthening. Aerobic regeneration will be carried out by walking along the hospital corridor, stationary bike and climbing stairs. Body balance therapy in closed systems in front of the mirror will also be included. After kinesiotherapy, the session will end with a vibration massage and relaxation of the whole body. Motivational breathing training will be used every 2 hours, 7 days a week, performed independently by the patient in the ward room. The physiotherapy process will be carried out 6 times a week and lasts 30-45 minutes a day. The duration of rehabilitation depends on the patient's condition: from 7 to 14 days.
Study: NCT06281509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.
Description: Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive tests to determine the presence or absence of the palmaris longus tendon in both hands.
Description: Schaeffer's test (flexion of the wrist while the pinky and thumb are pressed against each other) Thompson's test (wrist flexion with a clenched fist) Mishra test I (wrist flexion while the examiner pushes the hand back) Mashra test II (thumb opposition while flexing the wrist)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A small mobile ultrasound device will be used to further asses the presence of the tendon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: A small mobile ultrasound device will be used to further asses the presence of the tendon.
Study: NCT04574518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeaM OUT Intervention
Description: The TeaM OUT Intervention has 2 elements: 1) a letter that a) describes the nodule and the importance of cessation related to the pulmonary nodule (i.e. teachable moment) and b) notification that a Proactive IVR Quit line will initiate contact and 2) call(s) from the Proactive IVR Quit Line which a) offers smoking cessation resources and b) helps connect the patient to those resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Usual Care
Description: The Enhanced Usual Care arm also has two elements: 1) a letter that a) describes the nodule without linking it to smoking cessation (i.e. no teachable moment) with b) wording to contact an Optional IVR Quit line if desired and 2) the Optional IVR Quit line which a) offers smoking cessation resources and b) helps connect the patient to those resources.
Study: NCT05457699

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SBAR to PSMA-PET visible disease at maximal systemic therapy response.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no RT
Description: no SABR, continued systemic therapy per SOC
Study: NCT05325359

Intervention type: BEHAVIORAL
Intervention: L test
Description: It is an expanded version of the TUG and is designed to assess advanced functional ambulation with more detail available elsewhere. It is recorded when the participant gets up from the chair, walks 3 m to a cone, turns 90° to the right, continues to walk 7 m to the next cone, turns 180° left around the cone, then returns to the chair the same way. The test time is recorded, starting with the word go and ending with the participant's back touching the back of the chair.
Study: NCT05127460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.
Study: NCT05807282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventions to Decrease Heat Stress among Latinx Farmworkers in Idaho
Description: The interventions will be developed in collaboration with our study partners and will include increasing access to shade at the workplace, providing hydration packs to participants, and providing education regarding the signs and symptoms of occupational heat stress.
Study: NCT04140448

Intervention type: DRUG
Intervention: Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Description: Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML

Intervention type: DEVICE
Intervention: Ultra-wide Fluorescein Angiography
Description: Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina
Study: NCT06522425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based serious games
Description: The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness-based serious games
Description: The intervention consists of a single session using a digital serious game designed to teach mindfulness techniques for pain management. In addition to explaining mindfulness concepts, the game provides a variety of mindfulness exercises to help users manage and reduce pain perception. For example, it involves relaxation through breathing or becoming aware of the state of one's body and mind. Additionally, it includes various interaction elements such as touch, voice, and motion controls to increase user immersion.
Study: NCT05664893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib Oral Tablet
Description: 600mg per day during registration phase (3 cycles); de-escalation phase (600 to 200mg per day associated to radiotherapy) during 3 other cycles; maintenance phase until 24 months of treatment in total (600mg per day).~All over th etimme, hormonotherapy is received in concomitance
Study: NCT05043766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614
Description: PF614 is an oxycodone prodrug
Study: NCT05810402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liquid Biopsy
Description: 30mL blood sample:~* 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis~* 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL),~* 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell).
Study: NCT05828992

Intervention type: OTHER
Intervention: No intervention administered
Description: Survey only to gather people's experiences, opinions and needs.

Intervention type: OTHER
Intervention: No intervention administered
Description: Survey only to gather people's experiences, opinions and needs.

Intervention type: OTHER
Intervention: No intervention administered
Description: Survey only to gather people's experiences, opinions and needs.

Intervention type: OTHER
Intervention: No intervention administered
Description: Survey only to gather people's experiences, opinions and needs.

Intervention type: OTHER
Intervention: No intervention administered
Description: Survey only to gather people's experiences, opinions and needs.
Study: NCT05279872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80mg po qd 6 weeks
Study: NCT05251597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green exercise with aerobic exercise
Description: Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green exercise with aerobic exercise
Description: Green exercise is a type of exercise done outdoors. It is an advantageous type of exercise in benefiting from sunlight and reducing anxiety. It is mostly applied in the form of brisk walking in the open air.
Study: NCT06328140

Intervention type: DRUG
Intervention: Lurasidone
Description: Daily medication treatment

Intervention type: DRUG
Intervention: FDA Approved antidepressant treatment
Description: Daily treatment with an FDA approved antidepressant
Study: NCT04786769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: Intravenous ferric carboxymaltose according to baseline weight and hemoglobin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferric carboxymaltose
Description: Intravenous ferric carboxymaltose according to baseline weight and hemoglobin
Study: NCT05043766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF614
Description: PF614 is an oxycodone prodrug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Hydrochloride
Description: Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Hydrochloride
Description: Naltrexone HCl tablets, 50 mg, will be used to block the opioid effects in healthy volunteers

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin
Description: Bioequivalence single-dose comparison to OxyContin
Study: NCT06475963

Intervention type: OTHER
Intervention: surveys
Description: telephone survey